Medication-Assisted Treatment (MAT) for Alcohol Addiction

Most patients who come to me have already tried to stop drinking on their own, multiple times. What I hear again and again is: “I knew I needed to stop, I just couldn’t make myself stay stopped.” That is not a willpower problem. That is what chronic alcohol exposure does to the brain’s opioid and glutamate systems. Medication does not fix everything, but it addresses the part that willpower cannot touch on its own.

What Is Medication-Assisted Treatment for Alcohol?

Medication-Assisted Treatment, or MAT, means using a prescribed medication alongside therapy and support to treat alcohol use disorder (AUD). It is not prescribing a pill and sending someone home. The medication handles the neurochemical side of the problem. The therapy handles behaviour, triggers, and the reasons drinking took hold in the first place.

AUD is classified in the DSM-5 as a chronic, relapsing brain disorder, not a character flaw. Chronic alcohol exposure disrupts three key neurotransmitter systems: opioid signalling in the mesolimbic reward pathway, GABA-A receptor function (which controls sedation and anxiety), and glutamate activity via NMDA receptors. MAT targets these disruptions directly.

The goal varies by patient. Some people are aiming for full abstinence. Others are reducing heavy drinking days as a first step. The medications used, and how they are dosed, reflect that difference.

FDA-Approved and Clinically Used Medications to Stop Drinking Alcohol

There are currently three FDA-approved medications for AUD and one European-approved medication that is used widely in clinical practice. Each works differently and suits different patients.

Naltrexone — Blocking the Reward

Naltrexone works by blocking mu-opioid receptors in the brain’s reward pathway. When you drink alcohol, opioid peptides are released in the mesolimbic system, which generates the pleasurable “hit” that reinforces continued drinking. Naltrexone blocks that signal. Drinking becomes less rewarding, and the drive to keep going fades.

It comes in two forms. Oral naltrexone (ReVia) is 50mg daily. Extended-release injectable naltrexone (Vivitrol) is a monthly intramuscular injection, which removes the daily decision to take the pill. The COMBINE trial, the largest randomised trial of AUD pharmacotherapy to date, showed naltrexone reduced the percentage of heavy drinking days and increased time to first relapse compared to placebo.

One important genetic point: patients with the OPRM1 A118G variant (also called the Asn40Asp polymorphism) tend to respond better to naltrexone. This is not yet standard clinical practice to test for routinely, but it is increasingly part of pharmacogenomic-guided prescribing.

Acamprosate — Restoring Glutamate Balance

Acamprosate (Campral) targets a different problem. After someone stops drinking, the glutamate system, which drives excitatory brain signalling, remains overactive for weeks to months. This is what causes the restlessness, anxiety, sleep disruption, and persistent craving that characterises the post-acute withdrawal phase. Acamprosate dampens that glutamate overactivity by modulating NMDA receptors and supporting GABA tone.

It works best in patients who are already abstinent at the start of treatment and want to stay that way. The dose is 666mg three times daily. Because it is renally excreted rather than liver-metabolised, it is one of the safer options for patients with alcoholic liver disease. The EUCLID and COMBINE trials both confirmed its efficacy for abstinence maintenance, though COMBINE showed less clear advantage over naltrexone in a head-to-head comparison.

Disulfiram — The Deterrent Approach

Disulfiram (Antabuse) works on a completely different principle. It irreversibly inhibits ALDH (aldehyde dehydrogenase), the enzyme that breaks down acetaldehyde. Acetaldehyde is the toxic intermediate produced when your liver processes alcohol. When ALDH is blocked, acetaldehyde accumulates rapidly. Drinking even small amounts of alcohol causes flushing, nausea, vomiting, palpitations, and a severe headache within minutes.

This is not a subtle effect. It is genuinely unpleasant and in some cases dangerous, particularly in patients with cardiovascular disease.

Disulfiram works when adherence is guaranteed, which is why supervised daily dosing is strongly preferred over self-administration. The evidence for it in unsupervised settings is weak. In supervised settings, including inpatient or closely monitored outpatient programmes, it can be highly effective for patients who specifically want a hard external barrier against impulsive drinking.

Nalmefene — As-Needed Dosing for Harm Reduction

Nalmefene (Selincro) is approved in the EU but not the FDA. It works similarly to naltrexone at mu-opioid receptors but also acts as a kappa-opioid receptor modulator, which may help with the dysphoria and stress-driven drinking that characterises later-stage AUD.

The key clinical difference is dosing. Nalmefene is taken on an as-needed basis, one to two hours before anticipated drinking. This suits patients whose goal is reducing alcohol consumption rather than full abstinence, and fits the Koob-Volkow model of addiction well: it targets the reward and stress systems that drive binge-pattern drinking without requiring total elimination of alcohol as a precondition.

How MAT Works Alongside Therapy — Not Instead of It

Medication reduces the neurochemical noise. It makes cravings less loud and relapses less automatic. What it does not do is address the patterns, relationships, trauma, or habits that developed around drinking.

The most effective MAT programmes combine medication with cognitive-behavioural therapy (CBT), motivational enhancement therapy (MET), or twelve-step facilitation. CBT in particular targets the automatic thoughts and situational triggers that lead to drinking. It teaches the brain what to do in the moment medication has quietened the urge.

The pattern I see in clinic: patients who take naltrexone without any therapy tend to do better than patients who do neither, but they plateau. Patients who do therapy without medication tend to relapse at the first major stress event. Patients who do both tend to build durable sobriety. The data supports this, as the COMBINE trial found that the combination of naltrexone and CBT-based medical management produced the best abstinence outcomes.

Who Is a Candidate for MAT?

MAT is appropriate for anyone who meets the DSM-5 criteria for moderate to severe AUD, which means scoring 4 or higher on the 11-item AUD criteria (moderate) or 6 or higher (severe). The criteria cover things like failing to cut down despite trying, continuing to drink despite physical or psychological harm, and drinking interfering with work, relationships, or responsibilities.

It is also appropriate for mild AUD in patients with strong risk factors for progression: family history, co-occurring mental health conditions, or a pattern of rapid escalation.

There are exclusion criteria. Naltrexone cannot be used in anyone currently using opioids or who has opioid dependence, as it will precipitate immediate withdrawal. Disulfiram cannot be used in severe cardiac disease, psychosis, or pregnancy. Acamprosate requires eGFR above 30.

Your prescribing clinician will also want a liver function panel (AST, ALT, GGT, bilirubin) and a full medication list before starting any of these agents.

Managing Alcohol Withdrawal Before MAT Begins

MAT for relapse prevention is a different treatment phase from managing acute alcohol withdrawal. If you are physically dependent on alcohol, meaning your body has adapted to its presence and you experience shakes, sweating, anxiety, or nausea when you stop, you need medically supervised withdrawal management before starting maintenance MAT.

Acute alcohol withdrawal can escalate to seizures and a life-threatening condition called delirium tremens (DTs). The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol) is the standard clinical tool used to score withdrawal severity and guide medication decisions. Scores above 10 typically warrant pharmacological management, usually with benzodiazepines such as chlordiazepoxide (Librium), or in some protocols, gabapentin for milder presentations.

You can read more about the full progression of alcohol withdrawal and what to expect at each stage and the specific role of Librium in managing alcohol withdrawal.

MAT in a Residential Treatment Setting

In a residential programme, MAT is integrated from the start rather than added later. The first week focuses on medically supervised detoxification, with CIWA-Ar-guided withdrawal management. Once the acute withdrawal phase clears, typically within five to seven days for most patients, maintenance MAT can begin.

Residential programmes also allow direct observation of medication administration for disulfiram, which is one of the reasons disulfiram performs better in this setting than in purely outpatient care. They also allow the behavioural therapy to happen in concentrated form while the medication is achieving its initial effect.

The other advantage of inpatient treatment is that clinicians can monitor for side effects and adjust dosing without the patient having to navigate that process alone at home. Naltrexone can cause nausea in the first one to two weeks, which is manageable but often leads to patients self-discontinuing if they are unsupported.

How Effective Are These Medications? What the Data Actually Shows

Naltrexone reduces the risk of relapse to heavy drinking by roughly 17 percent compared to placebo, based on a 2014 Cochrane meta-analysis of 50 trials. It also reduces the number of drinks on drinking days and total drinking days. The injectable formulation shows similar efficacy with improved adherence.

Acamprosate roughly doubles the proportion of patients maintaining continuous abstinence at six months compared to placebo across multiple European trials. It performs particularly well in patients with high baseline anxiety and those who are highly motivated for abstinence.

Disulfiram shows the strongest effect in supervised settings, where compliance is assured. In unsupervised trials, the effect largely disappears. This is a supervision effect, not a medication effect.

Nalmefene reduces heavy drinking days by approximately 50 percent in trials run under the ESENSE 1 and ESENSE 2 programmes, and it is particularly effective in patients who are not ready for full abstinence as a goal.

MAT and Co-occurring Mental Health Conditions

Most patients with AUD have at least one co-occurring psychiatric condition. Depression, anxiety disorders, and PTSD are the most common. This matters for MAT because some medication choices interact with psychiatric medications, and some psychiatric conditions alter treatment response.

Naltrexone, by blocking opioid receptors, can sometimes dampen mood in patients already prone to depression. This is not universal, but it is worth monitoring in the first month of treatment. There is no direct contraindication with SSRIs or SNRIs, but the full picture of a patient’s psychiatric medication list matters.

Acamprosate’s effect on the glutamate-GABA axis may have mild anxiolytic benefit, which can help patients whose drinking was driven heavily by anxiety. Disulfiram is generally avoided in patients with active psychosis due to interactions with antipsychotics and the risk of disulfiram-induced psychosis at higher doses.

The bottom line: MAT in the context of dual diagnosis requires a clinician who can hold both conditions at once. Treating the alcohol without addressing the anxiety or depression, or vice versa, produces poorer outcomes than integrated management.

The line between heavy drinking and alcohol use disorder is not always obvious from the inside. DSM-5 defines moderate AUD as four or more of eleven criteria: failed attempts to cut down, spending significant time obtaining or recovering from alcohol, cravings, failing to meet obligations, continuing despite relationship or health consequences, giving up activities, tolerance, and withdrawal. If that list sounds familiar, it is worth a clinical conversation rather than another attempt to manage it alone.

At Phuket Island Rehab, MAT is delivered within a medically supervised residential programme. We assess liver function, withdrawal severity using the CIWA-Ar, and co-occurring conditions before selecting the right medication. The medication is part of a treatment plan that includes individual therapy, group work, and a structured aftercare plan. The goal is not just stopping drinking. It is giving you a real chance at staying stopped.

Medication-Assisted Treatment for alcohol addiction is evidence-based, clinically well-supported, and significantly underused. Naltrexone, acamprosate, disulfiram, and nalmefene each work through distinct mechanisms: opioid receptor blockade, glutamate normalisation, acetaldehyde accumulation, and partial opioid-kappa modulation respectively. They are not interchangeable. The right choice depends on whether the goal is abstinence or reduction, the patient’s liver function, their psychiatric profile, and the level of clinical supervision available. The evidence is clear that medication combined with structured psychological therapy outperforms either alone.

For anyone who has tried to stop or cut down and found that the pull to drink comes back despite their best intentions, that is not a failure of character. That is the opioid and glutamate systems doing what chronic alcohol exposure trained them to do. Medication can address that specific mechanism. What it cannot replace is the work of understanding why drinking took hold and building something different in its place. That is why the combination matters.

As John A. Smith of Phuket Island Rehab puts it: “When a patient tells me they knew they needed to stop but couldn’t stay stopped, that’s the moment I want to talk about naltrexone. Not because it fixes everything, but because it stops the brain from sabotaging the decision the patient has already made.”

What is the most effective medication to stop drinking alcohol?

Naltrexone has the strongest overall evidence base for reducing heavy drinking and preventing relapse, with a 17 percent reduction in relapse risk compared to placebo in the Cochrane meta-analysis. That said, acamprosate is the better choice for patients who are already abstinent and want to stay that way, particularly those with significant anxiety or sleep disruption in early recovery. The “most effective” medication depends on the individual patient’s goals, liver function, and co-occurring conditions.

Can I get medication to stop drinking without going to rehab?

Yes, naltrexone and acamprosate can be prescribed in an outpatient setting by a physician with addiction medicine training. However, physically dependent drinkers need medically supervised withdrawal management before starting maintenance medication, and that usually requires at least a short inpatient admission. For patients with moderate to severe AUD, outpatient MAT alone has lower success rates than residential treatment, partly because supervised dosing, daily monitoring, and integrated therapy produce better adherence.

How long do you need to take medication for alcohol use disorder?

Most clinical guidelines recommend at least six to twelve months of pharmacotherapy for moderate to severe AUD, with reassessment at that point. Some patients take naltrexone or acamprosate for two years or longer, particularly those with a history of multiple relapses. There is no clinical benefit to stopping medication prematurely. AUD is a chronic condition and treating it for only a few weeks is similar to treating hypertension for six weeks and then discontinuing medication.

Does naltrexone stop cravings completely?

Naltrexone reduces craving intensity by blocking the opioid reward signal that alcohol triggers, but it does not eliminate craving entirely. Most patients describe it as turning down the volume on the urge rather than silencing it. The medication addresses the neurochemical reinforcement loop. The psychological and situational triggers still need to be worked through in therapy. Patients who use naltrexone alongside CBT report significantly better craving control than those on medication alone.

Is it safe to take alcohol use disorder medication if I have liver disease?

Acamprosate is the safest option for patients with liver disease because it is renally cleared and does not undergo hepatic metabolism. Naltrexone is generally safe at standard doses in patients with compensated liver disease, but should be used cautiously and with regular liver function monitoring in patients with elevated transaminases above three to five times the upper limit of normal. Disulfiram is avoided in significant liver disease due to its own hepatotoxic potential and because the disulfiram reaction in the context of impaired hepatic function can be severe.

What happens if you drink on disulfiram?

Drinking any amount of alcohol while taking disulfiram causes a rapid, unpleasant reaction within five to fifteen minutes. Acetaldehyde accumulates because ALDH is blocked, producing flushing, severe headache, nausea and vomiting, palpitations, and a sensation of breathlessness. In severe cases, particularly with larger amounts of alcohol or in patients with cardiovascular disease, the reaction can cause hypotension, arrhythmia, and cardiovascular collapse. The reaction is not a side effect of the medication. It is the intended mechanism.

Can medication for alcohol use disorder be used for alcohol withdrawal?

The medications used for acute alcohol withdrawal are different from those used for long-term relapse prevention. Benzodiazepines, particularly chlordiazepoxide (Librium), are the first-line treatment for medically managed withdrawal, dosed according to CIWA-Ar scores. Gabapentin is used in some protocols for mild to moderate withdrawal. Naltrexone and acamprosate are not used during acute withdrawal. MAT for relapse prevention begins after the withdrawal phase has resolved, typically five to seven days after the last drink. You can read more about the signs and symptoms of alcohol withdrawal syndrome and how assessment is managed clinically.